Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia: Supplementary Material

Lloyd AC Chapman, Maite Aubry, Noémie Maset, Timothy W Russell, Edward S Knock, John A Lees, Henri-Pierre Mallet, Van-Mai Cao-Lormeau, Adam J Kucharski

1 Supplementary results

1.1 MCMC output

The trace plots for the fitted parameters in Figure S1 show successful convergence of the MCMC, and the histograms of the posterior distributions for the parameters in Figure S2 show that they are all identifiable from the data. There is some positive correlation between the beta parameters for nearby time periods (Figure S3), which is not surprising given the piecewise linear form of the transmission rate (Equation (1) in the main text). The transmission rate in August 2021 is strongly positively correlated with introduction date for the Delta variant, which is to be expected given that the a higher transmission rate can compensate for a later introduction date.



Figure S1: Trace plots for fitted parameters from MCMC. Plots show samples from full chain (50,000 iterations), including the burn-in, thinned by a factor of 10.



Figure S2: Prior (red lines) and posterior (histograms) distributions of fitted parameters



Figure S3: Posterior distributions and pairwise correlations of the fitted parameters. Parameter posterior distributions are shown on the diagonal, pairwise scatter plots in the lower triangle, and pairwise correlation coefficients in the upper triangle.

1.2 Age-stratified model fit



Figure S4: Fit of the model to age-stratified hospitalisation (left) and hospital death (right) data for French Polynesia from July 2020 to May 2022. Red points show data, black line and grey shaded area show median and 95% credible intervals of simulations of the fitted model, i.e. the uncertainty in the expected number of hospitalisations and deaths in the model. Note that this does not include uncertainty in the reporting process. Note different scales on vertical axes.



Figure S5: Fit of the model to age-stratified confirmed case data for French Polynesia from July 2020 to May 2022. Red points show data, black line and grey shaded area show median and 95% CI of simulations of the fitted model, i.e. the uncertainty in the expected number of cases in the model. Note that this does not include uncertainty in the reporting process and that there is a strong day-of-the-week effect in the reporting.



Figure S6: Fit of the model to age-stratified seroprevalence data from the two seroprevalence surveys conducted on Tahiti and Moorea by the Cellule Epi-surveillance COVID and the Health Department of French Polynesia in Feburary 2021, and on Tahiti by Institut Louis Malardé in November-December 2021. Red dots and bars show seroprevalence estimates and exact binomial 95% confidence intervals for the two sero-surveys, and black line and grey shaded region show median and 95% CI of seroprevalence from simulations of the model.

1.3 Impact of alternative lockdown timings

We estimate the counterfactual impact that starting the lockdowns during the first two COVID-19 waves earlier or later would have had on the numbers of symptomatic cases, hospitalisations and hospital deaths in each wave and overall by simulating different combinations of the dates of the estimated changes in transmission due to the lockdowns in the first two waves (Figure S9). For each combination of lockdown dates, we run 500 simulations with parameter values drawn from the posterior distribution of the parameters from the model fitting and compare the numbers of hospitalisations and hospital deaths to those in simulations with the same parameter values with the actual lockdown dates. This gives the results shown in Table S1 and Figure S7.

The differences in the overall numbers of symptomatic cases, hospitalisations and hospital deaths for the earlier and later lockdown timings are all relatively small, ranging from 1300 (95% CI 1100–1400) fewer cases, 211 (95% CI 190–233) fewer hospitalisations and 34 (95% CI 30–37) fewer deaths for starting both lockdowns 2 weeks earlier up to 700 (95% CI 600–800) more cases, 87 (95% CI 76–99) more hospitalisations and 15 (95% 2000CI 13–17) more deaths for starting the second lockdown 2 weeks later (Table 1). This is because starting the first lockdown either 2 weeks earlier or later would have increased the number of cases in the first wave — by 2300 (95% CI 2000–2600) and 5300 (95% CI 4800–5800) respectively — and a greater number of cases in the first wave would have resulted in greater accumulation of population immunity prior to the second wave and therefore fewer cases, hospitalisations and deaths in the second wave. Starting the lockdown earlier would have flattened the first wave (reduced its peak, but prolonged its duration), while starting it later would have increased the peak but shortened the duration (Figure S7). The former change would have resulted in 3700 (95% CI 3300–4100) fewer cases in the second wave, the latter 6100 (95% CI 5500–6700) fewer cases. Initiating the second lockdown 2 weeks earlier in addition to starting the first lockdown 2 weeks earlier would have decreased the size of the second wave by a further 1400 cases. Varying the lockdown timings in the first two waves would have had a limited impact on the size of the third wave, as the total number of infections across the first two waves would have remained similar (so the population-level immunity entering the third wave would have been similar) and the immune escape properties of the Omicron BA.1/BA.2 variants reduce the impact of the proportion previously infected on the size of the third wave.

Table S1: Median (95% CI) estimated total numbers of symptomatic cases, hospitalisations and hospital deaths in different COVID-19 waves in French Polynesia up to May 2022 for different counterfactual scenarios of the timings of the lockdowns in the 1st and 2nd waves and vaccination and booster rollouts.

	in a second second	(entro			nospita	lisation					Hospital de	a ths		
	Vave 1	Wave 2	Wave 3	Total	Wave 1		Wave 2	Wave 5	~	Total	Wave 1	Wave 2	Wave 3	Total
No change in 4	(0 (38.6 -	40.7 (39.8–	57.1 (56.7 -	138 $(137-$	783 (747-	1770 (1710 -	566	(547 -	3120(3020 -	132 (126–	282 (271–	95.9(92.7 -	510 (495
lockdown dates 4	(1.2)	41.6)	57.5)	(139)	(819)		1840)	586)		3230)	138)	(293)	99.3)	526)
1st lockdown 2 4	12.3 $(40.7-$	37 (36–	57.6 (57.2 -	137 (136–	827 (785 -	1590(1520 -	571	(552 -	2990(2880 -	139(132 -	252 $(241 -$	96.9(93.6 -	488 (47]
weeks earlier 4	13.7)	38.2)	57.9)	138)	867)		1660)	591)		(000)	146)	264)	100)	504)
1st lockdown 2 4	5.3 $(44.4 -$	34.6 $(33.7-$	57.9(57.5 -	138 (137–	898 (863 -	1460(1410-	573	(554 -	2940(2840 -	153(147-	231° (222^{-}	97.3(93.9-	481 (465
weeks later 4	(6.2)	35.4)	58.2)	(139)	934)		1530)	594)		3040)	(159)	242)	101)	498)
2nd lockdown 2 4	10.4 (39.1–	39.9(38.9 -	57.2 ($56.9-$	138 (136-	792 (755-	1710 $(1640 -$	567	(548 -	3070(2970 -	133 (127–	271 ($261-$	96.1(92.9 -	501 (484
weeks earlier 4	(1.7)	41)	57.6)	(139)	828)		1790)	587)		3180)	140)	284)	99.5)	518)
2nd lockdown 2 3	$9.6^{\circ}(38.3-$	42.2 $(41.5-$	56.7 $(56.3 -$	139 $(137-$	775 (739-	1870 ($1810-$	562	(543 -	$3210^{\circ}(3110^{-1})$	130° (124–	298° (289^{-}	95.1(91.9 -	524 (508
weeks later 4	0.8)	(42.9)	57.2)	140)	811)		1940)	582)		3310)	137)	(309)	98.5)	541)
Both lock- 4	[3.1] $(41.6-$	35.6(34.4 -	$57.8^{\circ}(57.5^{-})$	137 $(135-$	844 (802 -	$1490^{\circ}(1410^{-1})$	574	(554 -	$2910^{\circ}(2810^{\circ})$	142° $(135^{-}$	236° (224^{-}	97.4(94.1 -	476 (459
downs 2 weeks 4	14.6)	36.9)	58.2)	138)	885)		1570)	593)		3010)	149)	249)	101)	(492)
earlier														
Both lock- 4	15.3 (44.3 -	35.6 (34.9 -	57.5 (57.1 -	138 (137 -	968	862 -	1550 (1490 -	570	(550 -	3010 (2910 -	152 (146 -	245 ($236-$	96.6(93.2 -	494 (478
downs 2 weeks 4	(6.1)	36.3)	58)	139)	932)		1610)	590)		3120)	159)	255)	100)	512)
later														

Wave 1 = 20th July 2020 to 30th June 2021 Wave 2 = 1st July 2021 to 30th November 2021 Wave 3 = 1st December 2021 to 6th May 2022.



Figure S7: Impact of alternative lockdown scenarios on numbers of COVID-19 symptomatic cases.

1.4 Booster waning rate sensitivity analysis

Figure S8 shows the estimated impact of the booster campaign for the lower booster waning rate from [1]. The estimated numbers of cases, hospitalisations and hospital deaths averted under the different assumptions about the booster waning rate are shown in Table S2. The estimated impact of the booster campaign is sensitive to the assumed booster waning rate, with more than twice as many hospitalisations and hospital deaths estimated to have been averted with the lower booster waning rate.

Table S2: Estimated median (95% CI) cases, hospitalisations and hospital deaths averted due to booster campaign for different assumptions about booster waning rate

Booster waning rate, ζ_{i5}	Cases averted (thousands)	Hospitalisations averted	Hospital deaths averted
Base case $= 0.0025 [1]$	4.8 (4.8-4.9)	92~(89-95)	$17 \ (17 - 18)$
Lower $= 0.00057$ [2]	$8.1 \; (8-8.2)$	213(205-222)	44 (43 - 46)



Figure S8: Impact of booster programme on numbers of COVID-19 symptomatic cases, hospitalisations and hospital deaths relative to no boosters for lower booster waning rate from [2]. See blue lines in Figure 2 in main text for comparison with higher booster waning rate from [1].



Figure S9: Estimated transmission rate over time, $\beta(t)$. Black line shows median estimate, shaded region the 95% CI for the fitted model. Blue line and shaded region show the same for the "no lockdowns" counterfactual scenario.

2 Supplementary discussion

2.1 Limitations

We assume mixing within age groups is homogeneous for the entire French Polynesian population ($\sim 280,000$). However, French Polynesia consists of a large number of islands gathered in five archipelagos spread over 2000km [3], some of which do not have frequent transport links to the main islands of Tahiti and Moorea, which account for $\sim 210,000$ individuals, so mixing of the population is not completely homogeneous. We also assume that the seroprevalence estimates from the surveys conducted on Tahiti and Moorea were representative of seroprevalence on all the islands, when in fact there may have been considerable variation between islands. Ideally we would have focused the analysis on the Windward Islands, which include Tahiti and Moorea, as these account for the majority of the population, were the islands most affected by the epidemic, and are where the sero-survey estimates were most representative, but this was not possible as too many cases were missing location information.

There are some factors that may mean we underestimate the impact of the vaccination programme. These include the fact that our estimates of cases, hospitalisations and deaths averted are based on reported hospital deaths, while data on all-cause mortality for 2015-2021 [4] and model-based estimates of excess mortality [5] suggest there may have been considerable under-reporting of COVID-19 deaths in the Delta wave. We also assume that all severity parameters, such as the probability of death given hospitalisation, remained constant over the course of the epidemic, but the data suggests that a higher proportion of hospitalised individuals died during the Delta wave than the initial wave and the BA.1/BA.2 wave (possibly because of high pressure on health services), and that we have underestimated the number of hospital deaths among individuals aged 60+ years during the Delta wave (by approximately 30%). Furthermore, we do not account for hospitalisation. Since the main hospitals in French Polynesia reached capacity during the Delta wave, we may have underestimated the transmission rate during this period and thus the counterfactual number of deaths without vaccination (as hospital capacity in the counterfactual scenario would have been reached more quickly, leading to a faster accumulation of deaths in the community).

Some of the large uncertainty in the impact of the booster programme (4800–8100 symptomatic cases averted) stems from the structure of the model, in that we treat individuals whose booster protection wanes as returning to full susceptibility when they may in fact retain some protection against severe disease for a long period of time. However, we made this simplifying assumption due to the relatively limited data available on the rate at which booster protection wanes and to avoid increasing the complexity of the model further (e.g. with additional strata for waned booster protection), which would require more assumptions. Although it is based on data on the rate at which booster protection against Omicron BA.1 hospitalisation wanes [1], the base case estimate of booster impact at the lower end of the scale may be too pessimistic, and the upper end of the scale may be more representative.

Another potential source of underestimation of the impact of the booster programme is that we treat the Omicron BA.1 and BA.2 sublineages as the same, despite evidence that BA.2 is more transmissible than BA.1 [6–9], and may therefore cause higher infection rates in the absence of protection from boosters. To some extent the difference in transmissibility will be absorbed in the fitting of the transmission rate for the third wave, but the resulting averaged transmission rate will give a lower estimate for the number of cases, hospitalisations and deaths, averted in the latter half of the third wave when BA.2 was dominant and booster coverage was higher. Vaccine effectiveness and severity estimates for Omicron BA.2 are similar to those for BA.1 [10–14], however, so the difference in transmissibility should be the only source of error, and given the lower severity of the Omicron variants, the absolute error in numbers of hospitalisations and deaths averted is likely to be small.

We assume initial vaccine effectiveness and rates of waning of immunity are the same for all ages. However, there is evidence that vaccine effectiveness against symptomatic infection is lower and wanes more quickly in older age groups (≥ 65 years) than in younger age groups, at least for the Delta variant [15], which may introduce some bias into our estimates of vaccination impact. We also assume waning rates are the same for different variants and infection outcomes, but data suggests waning is faster against the Omicron BA.1 variant than the Delta variant [1] and that protection against severe outcomes wanes more slowly than that against infection [15]. Further work is needed to determine the extent to which these differences affect vaccine

impact estimates.

Finally, we have not fitted the model to the most recent waves in French Polynesia, caused mainly by the Omicron BA.5, BA.4, and BQ.1.1 variants, as doing so would arguably require significantly increasing the complexity of the model (or moving to a status-based approach to capturing the immune status of the population [16]) to account for repeat booster vaccinations and the increased transmissibility/immune escape of the BA.5 [17] and BQ.1.1 variants [18]. Hence we are not able to make projections of future incidence under different scenarios of increasing contact levels and introduction of new variants.

References

- Julia Stowe, Nick Andrews, Freja Kirsebom, Mary Ramsay, and Jamie Lopez Bernal. Effectiveness of covid-19 vaccines against omicron and delta hospitalisation, a test negative case-control study. *Nature Communications*, 13, 12 2022. ISSN 20411723. doi: 10.1038/s41467-022-33378-7.
- [2] Rosanna C. Barnard, Nicholas G. Davies, James D. Munday, Rachel Lowe, Gwenan M. Knight, Quentin J. Leclerc, Damien C. Tully, David Hodgson, Rachael Pung, Joel Hellewell, Mihaly Koltai, David Simons, Kaja Abbas, Adam J. Kucharski, Simon R. Procter, Frank G. Sandmann, Carl A.B. Pearson, Kiesha Prem, Alicia Showering, Sophie R. Meakin, Kathleen O'Reilly, Ciara V. McCarthy, Matthew Quaife, Kerry L.M. Wong, Yalda Jafari, Arminder K. Deol, Rein M.G.J. Houben, Charlie Diamond, Thibaut Jombart, C. Julian Villabona-Arenas, William Waites, Rosalind M. Eggo, Akira Endo, Hamish P. Gibbs, Petra Klepac, Jack Williams, Billy J. Quilty, Oliver Brady, Jon C. Emery, Katherine E. Atkins, Lloyd A.C. Chapman, Katharine Sherratt, Sam Abbott, Nikos I. Bosse, Paul Mee, Sebastian Funk, Jiayao Lei, Yang Liu, Stefan Flasche, James W. Rudge, Fiona Yueqian Sun, Graham Medley, Timothy W. Russell, Amy Gimma, Stéphane Hué, Christopher I. Jarvis, Emilie Finch, Samuel Clifford, Mark Jit, and W. John Edmunds. Modelling the medium-term dynamics of sars-cov-2 transmission in england in the omicron era. *Nature Communications*, 13, 12 2022. ISSN 20411723. doi: 10.1038/s41467-022-32404-y.
- [3] Maite Aubry, Noémie Maset, Lloyd Chapman, Aurélie Simon, Sophie Olivier, Raphaëlle Bos, Kiyojiken Chung, Iotefa Teiti, Adam Kucharski, Henri-Pierre Mallet, and Van-Mai Cao-Lormeau. Seroprevalence of sars-cov-2 antibodies in french polynesia and perspective for vaccine strategies. *Preprints*, 2022. doi: 10.20944/preprints202212.0386.v1.
- [4] Institut de la Statistique de la Polynésie française. Points etudes et bilans de la polynésie française, 2021. URL https://www.insee.fr/fr/information/4190491.
- [5] The Economist. The pandemic's true death toll, 2022. URL https://www.economist.com/ graphic-detail/coronavirus-excess-deaths-estimates.
- [6] Frederik Plesner Lyngse, Carsten Thure Kirkeby, Matthew Denwood, Lasse Engbo Christiansen, Kåre Mølbak, Camilla Holten Møller, Robert Leo Skov, Tyra Grove Krause, Morten Rasmussen, Raphael Niklaus Sieber, Thor Bech Johannesen, Troels Lillebaek, Jannik Fonager, Anders Fomsgaard, Frederik Trier Møller, Marc Stegger, Maria Overvad, Katja Spiess, and Laust Hvas Mortensen. Household transmission of sars-cov-2 omicron variant of concern subvariants ba.1 and ba.2 in denmark. *Nature Communications*, 13, 12 2022. ISSN 20411723. doi: 10.1038/s41467-022-33498-0.
- [7] Daichi Yamasoba, Izumi Kimura, Hesham Nasser, Yuhei Morioka, Naganori Nao, Jumpei Ito, Keiya Uriu, Masumi Tsuda, Jiri Zahradnik, Kotaro Shirakawa, Rigel Suzuki, Mai Kishimoto, Yusuke Kosugi, Kouji Kobiyama, Teppei Hara, Mako Toyoda, Yuri L. Tanaka, Erika P. Butlertanaka, Ryo Shimizu, Hayato Ito, Lei Wang, Yoshitaka Oda, Yasuko Orba, Michihito Sasaki, Kayoko Nagata, Kumiko Yoshimatsu, Hiroyuki Asakura, Mami Nagashima, Kenji Sadamasu, Kazuhisa Yoshimura, Jin Kuramochi, Motoaki Seki, Ryoji Fujiki, Atsushi Kaneda, Tadanaga Shimada, Taka aki Nakada, Seiichiro Sakao, Takuji Suzuki, Takamasa Ueno, Akifumi Takaori-Kondo, Ken J. Ishii, Gideon Schreiber, Hirofumi Sawa, Akatsuki Saito, Takashi Irie, Shinya Tanaka, Keita Matsuno, Takasuke Fukuhara, Terumasa Ikeda, and Kei Sato. Virological characteristics of the sars-cov-2 omicron ba.2 spike. *Cell*, 185:2103–2115.e19, 6 2022. ISSN 10974172. doi: 10.1016/j.cell.2022.04.035.

- [8] Kimihito Ito, Chayada Piantham, and Hiroshi Nishiura. Estimating relative generation times and reproduction numbers of omicron ba.1 and ba.2 with respect to delta variant in denmark. *Mathematical Biosciences and Engineering*, 19:9005–9017, 2022. ISSN 15510018. doi: 10.3934/mbe.2022418.
- [9] Antonio Lentini, Antonio Pereira, Ola Winqvist, and Björn Reinius. Monitoring of the sars-cov-2 omicron ba.1/ba.2 lineage transition in the swedish population reveals increased viral rna levels in ba.2 cases. Med, 3:636–643.e4, 9 2022. ISSN 26666340. doi: 10.1016/j.medj.2022.07.007.
- [10] UK Health Security Agency. Sars-cov-2 variants of concern and variants under investigation in england - technical briefing 39, 2022.
- [11] Nicole Wolter, Waasila Jassat, DATCOV-Gen author group, Anne von Gottberg, and Cheryl Cohen. Clinical severity of omicron lineage ba.2 infection compared with ba.1 infection in south africa. *The Lancet*, 400:93–95, 7 2022. doi: 10.1016/S0140-6736(22)00981-3.
- [12] Claudia Sievers, Benedikt Zacher, Alexander Ullrich, Matthew Huska, Stephan Fuchs, Silke Buda, Walter Haas, Michaela Diercke, Matthias an der Heiden, and Stefan Kröger. Sars-cov-2 omicron variants ba.1 and ba.2 both show similarly reduced disease severity of covid-19 compared to delta, germany, 2021 to 2022. Eurosurveillance, 27, 6 2022. ISSN 15607917. doi: 10.2807/1560-7917.ES.2022.27.22.2200396.
- [13] Joseph A. Lewnard, Vennis X. Hong, Manish M. Patel, Rebecca Kahn, Marc Lipsitch, and Sara Y. Tartof. Clinical outcomes associated with sars-cov-2 omicron (b.1.1.529) variant and ba.1/ba.1.1 or ba.2 subvariant infection in southern california. *Nature Medicine*, 28:1933–1943, 9 2022. ISSN 1546170X. doi: 10.1038/s41591-022-01887-z.
- [14] Freja C M Kirsebom, Nick Andrews, Julia Stowe, Samuel Toffa, Ruchira Sachdeva, Eileen Gallagher, Natalie Groves, Anne-Marie O'Connell, Meera Chand, Mark Ramsay, and Jamie Lopez Bernal. Covid-19 vaccine effectiveness against the omicron (ba.2) variant in england. *The Lancet Infectious Diseases*, 22:1153–1162, 8 2022. doi: 10.1016/S1473-3099(22)00309-7.
- [15] Nick Andrews, Elise Tessier, Julia Stowe, Charlotte Gower, Freja Kirsebom, Ruth Simmons, Eileen Gallagher, Simon Thelwall, Natalie Groves, Gavin Dabrera, Richard Myers, Colin N.J. Campbell, Gayatri Amirthalingam, Matt Edmunds, Maria Zambon, Kevin Brown, Susan Hopkins, Meera Chand, Shamez N. Ladhani, Mary Ramsay, and Jamie Lopez Bernal. Duration of protection against mild and severe disease by covid-19 vaccines. New England Journal of Medicine, 386:340–350, 1 2022. ISSN 0028-4793. doi: 10.1056/nejmoa2115481.
- [16] Adam J. Kucharski, Viggo Andreasen, and Julia R. Gog. Capturing the dynamics of pathogens with many strains. *Journal of Mathematical Biology*, 72:1–24, 1 2016. ISSN 14321416. doi: 10.1007/ s00285-015-0873-4.
- [17] Houriiyah Tegally, Monika Moir, Josie Everatt, Marta Giovanetti, Cathrine Scheepers, Eduan Wilkinson, Kathleen Subramoney, Zinhle Makatini, Sikhulile Moyo, Daniel G. Amoako, Cheryl Baxter, Christian L. Althaus, Ugochukwu J. Anyaneji, Dikeledi Kekana, Raquel Viana, Jennifer Giandhari, Richard J. Lessells, Tongai Maponga, Dorcas Maruapula, Wonderful Choga, Mogomotsi Matshaba, Mpaphi B. Mbulawa, Nokukhanya Msomi, Armand Phillip Bester, Mathilda Claassen, Deelan Doolabh, Innocent Mudau, Nokuzola Mbhele, Susan Engelbrecht, Dominique Goedhals, Diana Hardie, Nei Yuan Hsiao, Arash Iranzadeh, Arshad Ismail, Rageema Joseph, Arisha Maharaj, Boitshoko Mahlangu, Kamela Mahlakwane, Ashlyn Davis, Gert Marais, Koleka Mlisana, Anele Mnguni, Thabo Mohale, Gerald Motsatsi, Peter Mwangi, Noxolo Ntuli, Martin Nyaga, Luicer Olubayo, Botshelo Radibe, Yajna Ramphal, Upasana Ramphal, Wilhelmina Strasheim, Naume Tebeila, Stephanie van Wyk, Shannon Wilson, Alexander G. Lucaci, Steven Weaver, Akhil Maharaj, Yusasha Pillay, Michaela Davids, Adriano Mendes, Simnikiwe Mayaphi, Yeshnee Naidoo, Sureshnee Pillay, Tomasz Janusz Sanko, James E. San, Lesley Scott, Lavanya Singh, Nonkululeko A. Magini, Pamela Smith-Lawrence, Wendy Stevens, Graeme Dor, Derek Tshiabuila, Nicole Wolter, Wolfgang Preiser, Florette K. Treurnicht, Marietjie Venter, Georginah Chiloane, Caitlyn McIntyre, Aine O'Toole, Christopher Ruis, Thomas P. Peacock, Cornelius Roemer, Sergei L. Kosakovsky Pond, Carolyn Williamson, Oliver G. Pybus, Jinal N. Bhiman, Allison Glass, Darren P. Martin, Ben Jackson, Andrew Rambaut, Oluwakemi Laguda-Akingba, Simani Gaseitsiwe, Anne

von Gottberg, and Tulio de Oliveira. Emergence of sars-cov-2 omicron lineages ba.4 and ba.5 in south africa. *Nature Medicine*, 28:1785–1790, 9 2022. ISSN 1546170X. doi: 10.1038/s41591-022-01911-2.

[18] European Centre for Disease Prevention and Control. Spread of the sars-cov-2 omicron variant sub-lineage bq.1 in the eu/eea, 2022. URL https://www.ecdc.europa.eu/sites/default/files/ documents/Epi-update-BQ1.pdf.